Michael Sayer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Sayer has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Chan
School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA
2 shared publications D. T. Amm
Physics Department, Queen's University, Kingston, Ontario CANADA K7L 3N6
2 shared publications- David J. Johnson
Department of Family and Community Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
2 shared publications - K. Sreenivas
Department of Physics and Astrophysics, University of Delhi, Delhi, India
2 shared publications - Kord M. Kober
Department of Physiological Nursing, University of California, San Francisco, USA
2 shared publications Adam Olshen
University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Elsevier in JAPhA Pharmacotherapy
- Vol. 3 (2)
Disparities in sodium-glucose cotransporter-2 inhibitor usage between patients with and without cancer: A retrospective study
- 12 January 2026
- Published by Elsevier in JAPhA Pharmacotherapy
- Vol. 3 (2)
Open AccessDisparities in sodium-glucose cotransporter-2 inhibitor usage between patients with and without cancer: A retrospective study
- Open Access
- 25 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71067
A Data‐Driven Epigenetic Characterization of Morning Fatigue Severity in Oncology Patients Receiving Chemotherapy: Associations With Epigenetic Age Acceleration, Blood Cell Types, and Expression‐Associated Methylation
Background: Moderate‐to‐severe fatigue commonly occurs in patients with cancer. Given the numerous roles that epigenetic processes may play in the development and severity of fatigue, the purposes of this study were to (1) use a data‐driven discovery approach to evaluate for mechanisms underlying morning fatigue in a group of oncology patients receiving chemotherapy and (2) identify common biological mechanisms associated with morning fatigue severity across these independent epigenetic evaluations. Methods: Patients completed questionnaires during the week prior to their chemotherapy treatment. Severity of morning fatigue was evaluated using the Lee Fatigue Scale. Associations between morning fatigue severity and epigenetic aging acceleration (EAA), immune cell type compositions, and differential methylation of expression‐associated loci (eCpGs) in distal regions (i.e., upstream of a gene on the same chromosome) were evaluated. These results were then evaluated for common biological mechanisms. Results: High morning fatigue was associated with older epigenetic age, positive EAA, and higher levels of EAA. Patients of the “Fast ager” type were more likely to have high morning fatigue. Higher morning fatigue was associated with lower (CD4 memory, CD8 memory, and NK) and higher (neutrophil and T regulatory) estimated proportions of cell types. Morning fatigue severity was associated with one differentially methylated distal region containing five eCpGs mapping to three genes (i.e., CILP, ONECUT1, SLCO3A1). Preliminary support was found for the role of Inflammaging as a common biological mechanism for morning fatigue. Conclusions: This study provides an epigenetic characterization of morning fatigue in patients receiving chemotherapy. The findings suggest that biological aging, gene regulatory, and inflammatory processes may contribute to morning fatigue and provide future targets for therapeutic interventions.
- 25 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71067
Open AccessA Data‐Driven Epigenetic Characterization of Morning Fatigue Severity in Oncology Patients Receiving Chemotherapy: Associations With Epigenetic Age Acceleration, Blood Cell Types, and Expression‐Associated Methylation
Background: Moderate‐to‐severe fatigue commonly occurs in patients with cancer. Given the numerous roles that epigenetic processes may play in the development and severity of fatigue, the purposes of this study were to (1) use a data‐driven discovery approach to evaluate for mechanisms underlying morning fatigue in a group of oncology patients receiving chemotherapy and (2) identify common biological mechanisms associated with morning fatigue severity across these independent epigenetic evaluations. Methods: Patients completed questionnaires during the week prior to their chemotherapy treatment. Severity of morning fatigue was evaluated using the Lee Fatigue Scale. Associations between morning fatigue severity and epigenetic aging acceleration (EAA), immune cell type compositions, and differential methylation of expression‐associated loci (eCpGs) in distal regions (i.e., upstream of a gene on the same chromosome) were evaluated. These results were then evaluated for common biological mechanisms. Results: High morning fatigue was associated with older epigenetic age, positive EAA, and higher levels of EAA. Patients of the “Fast ager” type were more likely to have high morning fatigue. Higher morning fatigue was associated with lower (CD4 memory, CD8 memory, and NK) and higher (neutrophil and T regulatory) estimated proportions of cell types. Morning fatigue severity was associated with one differentially methylated distal region containing five eCpGs mapping to three genes (i.e., CILP, ONECUT1, SLCO3A1). Preliminary support was found for the role of Inflammaging as a common biological mechanism for morning fatigue. Conclusions: This study provides an epigenetic characterization of morning fatigue in patients receiving chemotherapy. The findings suggest that biological aging, gene regulatory, and inflammatory processes may contribute to morning fatigue and provide future targets for therapeutic interventions.
- 31 July 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (12) , 2924-2931
Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure
Importance and Objective: Identifying sources of sex-based disparities is the first step in improving clinical outcomes for female patients. Using All of Us data, we examined the association of biological sex with cost-related medication adherence (CRMA) issues in patients with cardiovascular comorbidities. Materials and Methods: Retrospective data collection identified the following patients: 18 and older, completing personal medical history surveys, having hypertension (HTN), ischemic heart disease (IHD), or heart failure (HF) with medication use history consistent with these diagnoses. Implementing univariable and adjusted logistic regression, we assessed the influence of biological sex on 7 different patient-reported CRMA outcomes within HTN, IHD, and HF patients. Results: Our study created cohorts of HTN (n = 3891), IHD (n = 5373), and HF (n = 2151) patients having CRMA outcomes data. Within each cohort, females were significantly more likely to report various cost-related medication issues: being unable to afford medications (HTN hazards ratio [HR]: 1.68, confidence interval [CI]: 1.33-2.13; IHD HR: 2.33, CI: 1.72-3.16; HF HR: 1.82, CI: 1.22-2.71), skipping doses (HTN HR: 1.76, CI: 1.30-2.39; IHD HR: 2.37, CI: 1.69-3.64; HF HR: 3.15, CI: 1.87-5.31), taking less medication (HTN HR: 1.86, CI: 1.37-2.45; IHD HR: 2.22, CI: 1.53-3.22; HF HR: 2.99, CI: 1.78-5.02), delaying filling prescriptions (HTN HR: 1.83, CI: 1.43-2.39; IHD HR: 2.02, CI: 1.48-2.77; HF HR: 2.99, CI: 1.79-5.03), and asking for lower cost medications (HTN HR: 1.41, CI: 1.16-1.72; IHD HR: 1.75, CI: 1.37-2.22; HF HR: 1.61, CI: 1.14-2.27). Discussion and Conclusion: Our results clearly demonstrate CRMA issues disproportionately affect female patients with cardiovascular comorbidities, which may contribute to the larger sex-based disparities in cardiovascular care. These findings call for targeted interventions and strategies to address these disparities and ensure equitable access to cardiovascular medications and care for all patients.
- 31 July 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (12) , 2924-2931
Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure
Importance and Objective: Identifying sources of sex-based disparities is the first step in improving clinical outcomes for female patients. Using All of Us data, we examined the association of biological sex with cost-related medication adherence (CRMA) issues in patients with cardiovascular comorbidities. Materials and Methods: Retrospective data collection identified the following patients: 18 and older, completing personal medical history surveys, having hypertension (HTN), ischemic heart disease (IHD), or heart failure (HF) with medication use history consistent with these diagnoses. Implementing univariable and adjusted logistic regression, we assessed the influence of biological sex on 7 different patient-reported CRMA outcomes within HTN, IHD, and HF patients. Results: Our study created cohorts of HTN (n = 3891), IHD (n = 5373), and HF (n = 2151) patients having CRMA outcomes data. Within each cohort, females were significantly more likely to report various cost-related medication issues: being unable to afford medications (HTN hazards ratio [HR]: 1.68, confidence interval [CI]: 1.33-2.13; IHD HR: 2.33, CI: 1.72-3.16; HF HR: 1.82, CI: 1.22-2.71), skipping doses (HTN HR: 1.76, CI: 1.30-2.39; IHD HR: 2.37, CI: 1.69-3.64; HF HR: 3.15, CI: 1.87-5.31), taking less medication (HTN HR: 1.86, CI: 1.37-2.45; IHD HR: 2.22, CI: 1.53-3.22; HF HR: 2.99, CI: 1.78-5.02), delaying filling prescriptions (HTN HR: 1.83, CI: 1.43-2.39; IHD HR: 2.02, CI: 1.48-2.77; HF HR: 2.99, CI: 1.79-5.03), and asking for lower cost medications (HTN HR: 1.41, CI: 1.16-1.72; IHD HR: 1.75, CI: 1.37-2.22; HF HR: 1.61, CI: 1.14-2.27). Discussion and Conclusion: Our results clearly demonstrate CRMA issues disproportionately affect female patients with cardiovascular comorbidities, which may contribute to the larger sex-based disparities in cardiovascular care. These findings call for targeted interventions and strategies to address these disparities and ensure equitable access to cardiovascular medications and care for all patients.
- Open Access
- 4 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7470
Current evidence supporting associations of DNA methylation measurements with survivorship burdens in cancer survivors: A scoping review
Introduction: Identifying reliable biomarkers that reflect cancer survivorship symptoms remains a challenge for researchers. DNA methylation (DNAm) measurements reflecting epigenetic changes caused by anti‐cancer therapy may provide needed insights. Given lack of consensus describing utilization of DNAm data to predict survivorship issues, a review evaluating the current landscape is warranted.Objective: Provide an overview of current studies examining associations of DNAm with survivorship burdens in cancer survivors.Methods: A literature review was conducted including studies if they focused on cohorts of cancer survivors, utilized peripheral blood cell DNAm data, and evaluated the associations of DNAm and survivorship issues.Results: A total of 22 studies were identified, with majority focused on breast (n = 7) or childhood cancer (n = 9) survivors, and half studies included less than 100 patients (n = 11). Survivorship issues evaluated included those related to neurocognition (n = 5), psychiatric health (n = 3), general wellness (n = 9), chronic conditions (n = 5), and treatment specific toxicities (n = 4). Studies evaluated epigenetic age metrics (n = 10) and DNAm levels at individual CpG sites or regions (n = 12) for their associations with survivorship issues in cancer survivors along with relevant confounding factors. Significant associations of measured DNAm in the peripheral blood samples of cancer survivors and survivorship issues were identified.Discussion/Conclusion: Studies utilizing epigenetic age metrics and differential methylation analysis demonstrated significant associations of DNAm measurements with survivorship burdens. Associations were observed encompassing diverse survivorship outcomes and timeframes relative to anti‐cancer therapy initiation. These findings underscore the potential of these measurements as useful biomarkers in survivorship care and research.
- 4 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7470
Open AccessCurrent evidence supporting associations of DNA methylation measurements with survivorship burdens in cancer survivors: A scoping review
Introduction: Identifying reliable biomarkers that reflect cancer survivorship symptoms remains a challenge for researchers. DNA methylation (DNAm) measurements reflecting epigenetic changes caused by anti‐cancer therapy may provide needed insights. Given lack of consensus describing utilization of DNAm data to predict survivorship issues, a review evaluating the current landscape is warranted.Objective: Provide an overview of current studies examining associations of DNAm with survivorship burdens in cancer survivors.Methods: A literature review was conducted including studies if they focused on cohorts of cancer survivors, utilized peripheral blood cell DNAm data, and evaluated the associations of DNAm and survivorship issues.Results: A total of 22 studies were identified, with majority focused on breast (n = 7) or childhood cancer (n = 9) survivors, and half studies included less than 100 patients (n = 11). Survivorship issues evaluated included those related to neurocognition (n = 5), psychiatric health (n = 3), general wellness (n = 9), chronic conditions (n = 5), and treatment specific toxicities (n = 4). Studies evaluated epigenetic age metrics (n = 10) and DNAm levels at individual CpG sites or regions (n = 12) for their associations with survivorship issues in cancer survivors along with relevant confounding factors. Significant associations of measured DNAm in the peripheral blood samples of cancer survivors and survivorship issues were identified.Discussion/Conclusion: Studies utilizing epigenetic age metrics and differential methylation analysis demonstrated significant associations of DNAm measurements with survivorship burdens. Associations were observed encompassing diverse survivorship outcomes and timeframes relative to anti‐cancer therapy initiation. These findings underscore the potential of these measurements as useful biomarkers in survivorship care and research.
- 28 August 2006
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
- Vol. 53 (9) , 1679-1684
Fabrication of PZT sol gel composite ultrasonic transducers using batch fabrication micromolding
A new micromolding technique for fabricating high-frequency (>20 MHz) ultrasound transducers has been developed. The technique combines sol gel processing with an epoxy-based, photo-resist Su-8 micromold to form miniature PZT structures. An advantage of this technique as compared to more traditional lithographic galvanforming and abforming (LIGA) processing is that the intermediate step of producing a nickel-plated mold is avoided. Instead, the PZT is formed directly using a photo-resist. The resulting structures can be fabricated with aspect ratios up to 3:1 and thicknesses up to 50 mu. We have successfully fabricated 50-mu thick linear array elements with 23-mu-wide elements separated by 15 kerfs. A 50-mu thick, 2.5-mm diameter, five-element annular array structure with 20-mu kerfs also has been fabricated. The micromolded PZT composite has a density of 5.7-5.8 plusmn 0.4 g/cm3 and a thickness coupling coefficient as high as 0.32
- 28 August 2006
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
- Vol. 53 (9) , 1679-1684
Fabrication of PZT sol gel composite ultrasonic transducers using batch fabrication micromolding
A new micromolding technique for fabricating high-frequency (>20 MHz) ultrasound transducers has been developed. The technique combines sol gel processing with an epoxy-based, photo-resist Su-8 micromold to form miniature PZT structures. An advantage of this technique as compared to more traditional lithographic galvanforming and abforming (LIGA) processing is that the intermediate step of producing a nickel-plated mold is avoided. Instead, the PZT is formed directly using a photo-resist. The resulting structures can be fabricated with aspect ratios up to 3:1 and thicknesses up to 50 mu. We have successfully fabricated 50-mu thick linear array elements with 23-mu-wide elements separated by 15 kerfs. A 50-mu thick, 2.5-mm diameter, five-element annular array structure with 20-mu kerfs also has been fabricated. The micromolded PZT composite has a density of 5.7-5.8 plusmn 0.4 g/cm3 and a thickness coupling coefficient as high as 0.32
- 1 September 1997
- Published by Taylor & Francis in Integrated Ferroelectrics
- Vol. 17 (1-4) , 1-10
Emerging technologies for ferroelectric films and coatings
Chemical solution deposition (CSD) allows the integration of ferroelectric and piezoelectric coatings with both silicon technology and in large scale macroscopic devices. Applications of coatings as actuators, in high frequency ultrasonic transducers and for piezoelectric transformers are discussed.
- 1 September 1997
- Published by Taylor & Francis in Integrated Ferroelectrics
- Vol. 17 (1-4) , 1-10
Emerging technologies for ferroelectric films and coatings
Chemical solution deposition (CSD) allows the integration of ferroelectric and piezoelectric coatings with both silicon technology and in large scale macroscopic devices. Applications of coatings as actuators, in high frequency ultrasonic transducers and for piezoelectric transformers are discussed.
- 1 January 1990
- Published by Springer Nature in MRS Proceedings
- Vol. 200
Measuring Fatigue in PZT Thin Films
- 1 January 1990
- Published by Springer Nature in MRS Proceedings
- Vol. 200
Measuring Fatigue in PZT Thin Films
- 1 January 1990
- Published by Springer Nature in MRS Proceedings
- Vol. 200
Characterization of Lead Zirconate Titanate (PZT) - Indium Tin Oxide (ITO) Thin Film Interface
The interface between ultrathin sputtered lead zirconate titanate (PZT) films and a conductive electrode (indium tin oxide-ITO) is investigated. Structural and compositional changes at the PZT-ITO interface have been examined by surface analysis and depth profiling techniques of glancing angle X-ray diffraction, Rutherford backscattering (RBS), SIMS, Auger electron spectroscopy (AES), and elastic recoil detection analysis (ERDA). Studies indicate significant interdiffusion of lead into the underlying ITO layer and glass substrate with a large amount of residual stress at the interface. Influence of such compositional deviations at the interface is correlated to an observed thickness dependence in the dielectric properties of PZT films.
- 1 January 1990
- Published by Springer Nature in MRS Proceedings
- Vol. 200
Characterization of Lead Zirconate Titanate (PZT) - Indium Tin Oxide (ITO) Thin Film Interface
The interface between ultrathin sputtered lead zirconate titanate (PZT) films and a conductive electrode (indium tin oxide-ITO) is investigated. Structural and compositional changes at the PZT-ITO interface have been examined by surface analysis and depth profiling techniques of glancing angle X-ray diffraction, Rutherford backscattering (RBS), SIMS, Auger electron spectroscopy (AES), and elastic recoil detection analysis (ERDA). Studies indicate significant interdiffusion of lead into the underlying ITO layer and glass substrate with a large amount of residual stress at the interface. Influence of such compositional deviations at the interface is correlated to an observed thickness dependence in the dielectric properties of PZT films.